Treatment of Ovarian Cancer Patients
common.study.values.description
“A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy”
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Rucaparib
Oral rucaparib will be administered twice daily
Drug - Nivolumab
IV nivolumab will be administered once every 4 weeks
Drug - Placebo Oral Tablet
Placebo tablets will be administered twice daily
Drug - Placebo IV Infusion
IV placebo will be administered once every 4 weeks
participant.views.study.view.additional
participant.views.study.view.scientific-title
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
common.study.values.clinical-trial-id
NCT03522246
participant.views.study.view.id
RdGGKd
